Nature Communications (Apr 2016)

A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer

  • Sherry Y. Wu,
  • Rajesha Rupaimoole,
  • Fangrong Shen,
  • Sunila Pradeep,
  • Chad V. Pecot,
  • Cristina Ivan,
  • Archana S. Nagaraja,
  • Kshipra M. Gharpure,
  • Elizabeth Pham,
  • Hiroto Hatakeyama,
  • Michael H. McGuire,
  • Monika Haemmerle,
  • Viviana Vidal-Anaya,
  • Courtney Olsen,
  • Cristian Rodriguez-Aguayo,
  • Justyna Filant,
  • Ehsan A. Ehsanipour,
  • Shelley M. Herbrich,
  • Sourindra N. Maiti,
  • Li Huang,
  • Ji Hoon Kim,
  • Xinna Zhang,
  • Hee-Dong Han,
  • Guillermo N. Armaiz-Pena,
  • Elena G. Seviour,
  • Sue Tucker,
  • Min Zhang,
  • Da Yang,
  • Laurence J. N. Cooper,
  • Rouba Ali-Fehmi,
  • Menashe Bar-Eli,
  • Ju-Seog Lee,
  • Prahlad T. Ram,
  • Keith A. Baggerly,
  • Gabriel Lopez-Berestein,
  • Mien-Chie Hung,
  • Anil K. Sood

DOI
https://doi.org/10.1038/ncomms11169
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 14

Abstract

Read online

The formation of blood vessels in tumours, angiogenesis, is a promising target for therapy. Here, the authors show that microRNA192 has anti-angiogenic functions and negatively regulates EGR1 and HOXB9, and that delivery of this microRNA to tumours in vivocan reduce angiogenesis and tumour growth.